We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Cytheris Announces Publication of Preclinical Study in Journal of Immunology Showing Interleukin-7 Promotes T Cell Viability, Trafficking and Functionality While Improving Survival in Sepsis

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival. Sepsis, a highly lethal disorder which occurs during severe overwhelming infection, is the most common cause of death in most intensive care units in developed countries, annually striking an estimated 750,000 people in the United States alone, resulting in the death of more than 220,000 people per year.


The paper entitled "IL-7 Promotes T Cell Viability, Trafficking and Functionality and Improves Survival in Sepsis" is prepublished online in The Journal of Immunology, the journal of The American Association of Immunologists (Jacqueline Unsinger, Margaret McGlynn, Kevin R. Kasten, Andrew S. Hoekzema, Eizo Watanabe, Jared T. Muenzer, Jacquelyn S. McDonough, Johannes Tschoep, Thomas A. Ferguson, Jonathan E. McDunn, Michel Morre, David A. Hildeman, Charles C. Caldwell, and Richard S. Hotchkiss, March 3, 2010; www.jimmunol.org/cgi/content/abstract/jimmunol.0903151v1).